Deals9 Sept 2025, 08:53 am
Glenmark Pharmaceuticals Receives $700 Million Upfront Payment from AbbVie
AI Summary
Glenmark Pharmaceuticals Ltd. has announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 million from AbbVie. This payment is in accordance with the contractual terms of an exclusive global licensing agreement for IGI’s lead investigational asset, ISB 2001, across North America, Europe, Japan, and Greater China markets. The agreement was initially announced in a media release dated 10th July 2025.
Key Highlights
- Glenmark Pharmaceuticals receives $700 million upfront payment from AbbVie
- Payment is in accordance with the contractual terms of an exclusive global licensing agreement
- Agreement covers Ichnos Glenmark Innovation’s lead investigational asset, ISB 2001
- Covers markets in North America, Europe, Japan, and Greater China
- Announcement follows a previous media release dated 10th July 2025